Best Peptides for Weight Loss

How Weight Loss Peptides Work: Mechanisms Overview

Weight loss peptides operate through distinct biological mechanisms: appetite suppression (GLP-1 agonists), metabolic rate elevation (5-Amino-1MQ, Tesamorelin), lipid mobilization (AOD-9604), and energy partitioning (Tirzepatide's GIP component). Unlike stimulant-based fat burners (which raise cortisol and crash), these peptides work with endogenous systems—GLP-1 receptors exist naturally throughout the gut and brain, controlling hunger and satiety; metabolic peptides upregulate mitochondrial oxidative capacity. The result: sustainable weight loss with preserved muscle mass and improved body composition metrics beyond simple scale weight reduction.

Semaglutide: FDA-Approved GLP-1 Agonist (#1 for Results)

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist with the strongest real-world weight loss data: 15-18% bodyweight reduction over 68 weeks in clinical trials, with users reporting 1-2 lbs weekly loss after initial dose titration. Semaglutide slows gastric emptying (food stays in your stomach longer, maintaining fullness), upregulates satiety signaling in the hypothalamus, and reduces hedonic eating (food cravings for calorie-dense pleasure foods). The mechanism is remarkably elegant: it doesn't block calories; it reduces caloric desire to match caloric needs.

Dosing: 0.25-0.5mg weekly subcutaneous injection for weight loss (lower than diabetes dosing). Titrate slowly over 4-6 weeks to minimize GI side effects. Expected weight loss: 0.5-2 lbs/week depending on baseline metabolic rate and dietary compliance. Cost: $300-400/month for research versions or $900-1300/month for pharmaceutical (Wegovy) through insurance. Results visible by week 4-6 of consistent dosing.

Tirzepatide: Dual GLP-1/GIP Agonist (Mounjaro/Zepbound)

Tirzepatide activates both GLP-1 and GIP receptors, combining appetite suppression with improved insulin sensitivity and enhanced pancreatic beta cell function. Clinical trials show 20-22% bodyweight reduction—superior to Semaglutide alone. The dual mechanism addresses multiple weight loss pathways: GLP-1 reduces hunger, GIP improves glucose homeostasis (preventing metabolic crashes that trigger cravings). Users report more stable energy and fewer cravings than with GLP-1 monotherapy.

Dosing: 2.5-15mg weekly subcutaneous, titrated slowly. Titration is critical: jumping to high doses produces severe nausea and vomiting. Cost: $800-1300/month through insurance (Mounjaro). Research versions: $400-600/month. Expect results by week 3-4, with accelerating weight loss weeks 8-12 as dose reaches therapeutic levels.

AOD-9604: Lipid Mobilization Peptide

AOD-9604 is a C-terminal fragment of human growth hormone that triggers lipolysis (fat cell breakdown) without stimulating growth. Unlike Semaglutide (which reduces appetite), AOD-9604 increases the rate at which adipose tissue mobilizes stored triglycerides for fuel. It's particularly effective for localized fat loss—users report preferential loss from visceral fat deposits (belly fat), which is metabolically harmful and difficult to target. Dosing: 300-600mcg daily subcutaneous injection. Results emerge slowly (3-8 weeks) but compound to 8-15 lbs over 12 weeks when combined with resistance training and adequate protein.

Advantage: minimal appetite suppression (useful for those who don't want reduced hunger) and excellent muscle preservation. Disadvantage: slower acting than Semaglutide and less clinically studied. Best stacked with Semaglutide or CJC-1295+Ipamorelin for comprehensive weight loss and body recomposition.

5-Amino-1MQ: Metabolic Rate Elevation

5-Amino-1MQ increases basal metabolic rate 10-15% by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme that suppresses mitochondrial biogenesis and NAD+ synthesis. Higher NAD+ levels drive SIRT1/PGC-1alpha activation, creating a metabolic upshift. Users report increased resting energy expenditure, improved exercise capacity, and sustained energy without stimulant crash. Dosing: 25-50mg daily subcutaneous or oral (oral absorption ~30%). Results visible in 2-4 weeks as the metabolic shift compounds.

Particularly valuable during caloric restriction, when metabolic adaptation normally suppresses energy expenditure—5-Amino-1MQ counteracts this. Users lose weight on calories that would normally plateau. Stack with Semaglutide for synergistic effect: appetite control (Semaglutide) + metabolic elevation (5-Amino-1MQ) = rapid, sustainable loss.

Tesamorelin and CJC-1295+Ipamorelin: GH-Driven Body Recomposition

These GHRH/GHRP agonists elevate growth hormone, which increases lipolysis and preserves/builds lean mass during weight loss. Tesamorelin (a GHRH analog) increases GH 2-3x baseline; CJC-1295+Ipamorelin produces similar GH elevation. The advantage during caloric deficit: sustained muscle mass. Users on GH-stimulating peptides lose fat while maintaining or gaining strength, versus traditional weight loss where 25-30% of loss is lean tissue.

Dosing: Tesamorelin 2mg daily; CJC-1295 (non-DAC) 100-200mcg 2-3x weekly + Ipamorelin 100-200mcg before bed. Results: improved body composition (less muscle loss), enhanced skin quality (collagen synthesis), and accelerated fat loss. Timeline: 4-6 weeks for visible lean mass preservation effects. Cost: $100-300/month.

Retatrutide: Triple GLP-1/GIP/GCG Agonist (Emerging)

Retatrutide combines GLP-1, GIP, and glucagon receptor agonism, creating a triple-action weight loss mechanism. Early clinical data shows 24-28% bodyweight reduction—exceeding Tirzepatide. The glucagon component increases thermogenesis (metabolic heat production) and fat oxidation. Retatrutide is not yet widely available but represents the next generation of weight loss peptides. When available, expect high costs ($1500-2000/month) and powerful effects requiring careful medical supervision.

Weight Loss Peptide Stacking Protocols

Basic Fat Loss Stack: Semaglutide 0.5mg weekly + 5-Amino-1MQ 50mg daily. Expected result: 1-2 lbs/week, preserved muscle, stable energy.

Aggressive Recomposition Stack: Tirzepatide 10-15mg weekly + AOD-9604 500mcg daily + CJC-1295/Ipamorelin before bed 3x weekly. Expected result: 2-3 lbs/week fat loss with lean mass gain, superior body composition.

Metabolic Elevation Stack: 5-Amino-1MQ 50mg daily + Tesamorelin 2mg daily + modest caloric deficit (500 kcal). Expected result: 0.75-1.5 lbs/week with strength preservation and skin improvement.

Maintenance/Long-term Stack: Semaglutide 0.25-0.5mg weekly (lowest effective dose) + Tesamorelin 1mg daily for sustained appetite control and muscle preservation 6-12 months post-weight loss.

Cost-Benefit Analysis: Pharmaceutical vs Research Peptides

Semaglutide (Wegovy): $900-1300/month through insurance, FDA-approved, reliable quality. AOD-9604: $300-500/month research version, no insurance coverage, efficacy variable by vendor. Tirzepatide (Zepbound/Mounjaro): $800-1500/month, FDA-approved. 5-Amino-1MQ: $150-300/month research, experimental efficacy. For fastest, most predictable results, Semaglutide or Tirzepatide through medical channels is justified. For cost-conscious approaches, Semaglutide research versions ($300-400/month) + AOD-9604 ($350/month) = $700/month for comparable results at half the cost of pharmaceutical options.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

FAQ: Weight Loss Peptides